SCHEMBL22967390

SCHEMBL22967390

CC(C)Oc1ccc(OCc2ccccn2)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.58
ALDH1A1 P00352 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
PARP10 Q53GL7 1/20 0.55
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
MAOB P27338 1/20 0.51
TP53 P04637 1/20 0.48
SYK P43405 5/20 0.48
AURKB Q96GD4 1/20 0.48
INCENP Q9NQS7 1/20 0.48
ADAMTS4 O75173 1/20 0.47
HPGD P15428 1/20 0.46
ALOX5AP P20292 1/20 0.45
ALOX5 P09917 1/20 0.45
KCNH2 Q12809 1/20 0.44
MAOA P21397 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16638704 0.83 KDM4E (0.58) KDM4EALDH1A1SMN1; SMN2PARP10CYP1A2
SCHEMBL22967393 0.81 ALDH1A1 (0.63) KDM4EALDH1A1SMN1; SMN2PARP10CYP1A2
SCHEMBL169753 0.81 SMN1; SMN2 (0.63) KDM4EALDH1A1SMN1; SMN2PARP10CYP1A2
SCHEMBL1073540 0.81 SYK (0.68) KDM4EALDH1A1SMN1; SMN2PARP10CYP1A2
SCHEMBL17712548 0.81 KDM4E (0.55) KDM4EALDH1A1SMN1; SMN2PARP10CYP1A2
SCHEMBL20655724 0.80 SYK (0.51) SYKAURKBINCENPKCNH2
SCHEMBL6445371 0.80 KCNH2 (0.67) KDM4EALDH1A1SMN1; SMN2PARP10CYP1A2
SCHEMBL8677742 0.80 KDM4E (0.66) KDM4EALDH1A1SMN1; SMN2PARP10CYP1A2
Hydrochloric Acid SCHEMBL22159185 0.80 PARP10 (0.55) KDM4EALDH1A1SMN1; SMN2PARP10CYP1A2
SCHEMBL14464038 0.80 ALDH1A1 (0.54) KDM4EALDH1A1SMN1; SMN2PARP10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-10 US disclosed
EP-3760633-B1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2021-12-15 EP disclosed
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2021-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof WNK1, WNK2, WNK3 KDM4E 2166/4885ALDH1A1 1467/4885SMN1; SMN2 3866/4885
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF WNK1, WNK2, WNK3 KDM4E 2166/4885ALDH1A1 1467/4885SMN1; SMN2 3866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.